FI20115870A0 - Neuroprotektiiviset soluihin tunkeutuvat peptidit - Google Patents
Neuroprotektiiviset soluihin tunkeutuvat peptiditInfo
- Publication number
- FI20115870A0 FI20115870A0 FI20115870A FI20115870A FI20115870A0 FI 20115870 A0 FI20115870 A0 FI 20115870A0 FI 20115870 A FI20115870 A FI 20115870A FI 20115870 A FI20115870 A FI 20115870A FI 20115870 A0 FI20115870 A0 FI 20115870A0
- Authority
- FI
- Finland
- Prior art keywords
- peptides
- seq
- disease
- amino acids
- penetrating peptides
- Prior art date
Links
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 title abstract 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 title abstract 2
- 230000000324 neuroprotective effect Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract 1
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 230000000975 bioactive effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000005064 dopaminergic neuron Anatomy 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 210000003061 neural cell Anatomy 0.000 abstract 1
- 239000003900 neurotrophic factor Substances 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20115870A FI20115870A0 (fi) | 2011-09-05 | 2011-09-05 | Neuroprotektiiviset soluihin tunkeutuvat peptidit |
| PCT/FI2012/050859 WO2013034805A1 (en) | 2011-09-05 | 2012-09-05 | Neuroprotective cell-penetrating peptides |
| EP12830062.1A EP2753641A4 (en) | 2011-09-05 | 2012-09-05 | NEUROPROTECTIVE CELL PENETRATING PEPTIDES |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20115870A FI20115870A0 (fi) | 2011-09-05 | 2011-09-05 | Neuroprotektiiviset soluihin tunkeutuvat peptidit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI20115870A0 true FI20115870A0 (fi) | 2011-09-05 |
Family
ID=44718780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI20115870A FI20115870A0 (fi) | 2011-09-05 | 2011-09-05 | Neuroprotektiiviset soluihin tunkeutuvat peptidit |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2753641A4 (fi) |
| FI (1) | FI20115870A0 (fi) |
| WO (1) | WO2013034805A1 (fi) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013212284A1 (en) * | 2012-01-24 | 2014-08-14 | University Of Massachusetts | Soluble MANF in pancreatic beta-cell disorders |
| WO2014191630A2 (en) * | 2013-05-28 | 2014-12-04 | Helsingin Yliopisto | Non-human animal model encoding a non-functional manf gene |
| US10265380B2 (en) | 2014-03-05 | 2019-04-23 | Amarantus Bioscience Holdings, Inc. | Method of administering MANF for the protection of sensory cells |
| WO2015149005A1 (en) * | 2014-03-28 | 2015-10-01 | Buck Institute For Research On Aging | Methods and compositions for modulating the immune system |
| US20170157243A1 (en) * | 2014-06-24 | 2017-06-08 | University Of Massachusetts | MANF as a Regulator of Immune System Function |
| JP7201432B2 (ja) | 2015-11-18 | 2023-01-10 | ヘランティス ファーマ ピーエルシー | 中枢神経系疾患の鼻腔内治療に使用するためのｃｄｎｆまたはｍａｎｆを含む組成物 |
| MX2019013157A (es) * | 2017-05-04 | 2020-08-03 | Helsingin Yliopisto | Fragmentos de cdnf y manf c-terminales, composiciones farmaceuticas que los comprenden y usos de los mismos. |
| EP3774858B1 (en) | 2018-03-29 | 2025-07-30 | MyNeuroCure Oy | C-terminal cdnf fragments having neuroprotective effect |
| EP3838912A1 (en) | 2019-12-20 | 2021-06-23 | Herantis Pharma Oyj | Retro-inverso peptides |
| EP3838345A1 (en) | 2019-12-20 | 2021-06-23 | Herantis Pharma Oyj | Macrocyclic peptides |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999043693A1 (en) * | 1998-02-26 | 1999-09-02 | Human Genome Sciences, Inc. | 36 human secreted proteins |
| WO2001022920A2 (en) * | 1999-09-29 | 2001-04-05 | Human Genome Sciences, Inc. | Colon and colon cancer associated polynucleotides and polypeptides |
| US20030109457A1 (en) * | 2001-10-25 | 2003-06-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| DE60238038D1 (de) * | 2001-03-20 | 2010-12-02 | Cns Protein Therapeutics Inc | Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen |
| WO2002079246A2 (en) * | 2001-03-30 | 2002-10-10 | Geneprot, Inc. | Human arginine-rich protein-related compositions |
| WO2004050688A1 (en) * | 2002-12-02 | 2004-06-17 | Xenome Ltd | NOVEL χ-CONOTOXIN PEPTIDES (-II) |
| PL1969003T3 (pl) * | 2005-12-14 | 2011-05-31 | Herantis Pharma Plc | Zastosowanie białka czynnika neurotroficznego |
| FI20080326A0 (fi) * | 2008-04-30 | 2008-04-30 | Licentia Oy | Neurotroofinen tekijä MANF ja sen käytöt |
-
2011
- 2011-09-05 FI FI20115870A patent/FI20115870A0/fi not_active Application Discontinuation
-
2012
- 2012-09-05 WO PCT/FI2012/050859 patent/WO2013034805A1/en not_active Ceased
- 2012-09-05 EP EP12830062.1A patent/EP2753641A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013034805A1 (en) | 2013-03-14 |
| EP2753641A4 (en) | 2015-06-24 |
| EP2753641A1 (en) | 2014-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI20115870A0 (fi) | Neuroprotektiiviset soluihin tunkeutuvat peptidit | |
| MX359516B (es) | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. | |
| NZ703341A (en) | Compositions comprising apomorphine and organic acids and uses thereof | |
| NZ621868A (en) | Growth hormone polypeptides and methods of making and using same | |
| NZ621196A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| PH12013502609A1 (en) | Compositions, uses and methods for treatment of metabolic disorders and diseases | |
| WO2017009843A3 (en) | Compositions, articles of manufacture and methods for treating cancer | |
| NZ611878A (en) | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides | |
| JO3476B1 (ar) | بروتينات مندمجة لعلاج الاضطرابات الايضية | |
| MX2012001194A (es) | Peptidos tau antigenicos y usos de los mismos. | |
| EA201491155A1 (ru) | Новые мутантные про-нрф и их применение для получения бета-нрф | |
| CY1112241T1 (el) | Θραυσματα πεπτιδιου για διεγερση συνθεσης πρωτεϊνων εξωκυτταρικης μητρας | |
| MX2012002502A (es) | Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos. | |
| MX347504B (es) | Formulaciones concentradas de proteina y usos de las mismas. | |
| WO2014085365A3 (en) | Compositions and methods for treatment of metabolic disorders and diseases | |
| UY33222A (es) | Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas | |
| EP4349360A3 (en) | Peptide exhibiting wrinkle-improving activity and uses thereof | |
| MX2013010910A (es) | Peptidos neuroprotectores. | |
| EA201290856A1 (ru) | Стабилизированная фармацевтическая композиция | |
| NZ590469A (en) | Treatment of rheumatoid arthritis with human beta defensins (1-4) | |
| PH12015502005A1 (en) | New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy | |
| RU2013111675A (ru) | Рекомбинантный fc-гибридный белок пятого домена фибронектина типа iii dcc | |
| MX2015007402A (es) | Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos. | |
| MX2017002476A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. | |
| NZ629964A (en) | Method for treating inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application lapsed |